• Yesim Dargaud, Lucia Rugeri, Marie Christine Vergnes, Brigitte Arnuti, Paula Miranda, Claude Negrier, Audrey Bestion, Hélène Desmurs-Clavel, Jacques Ninet, Pascal Gaucherand, Rene Charles Rudigoz, Michel Berland, Fabienne Champion, and Marie Christine Trzeciak.
• Unité d'Hémostase Clinique, Hôpital Edouard Herriot, Université Lyon 1, Lyon, France. ydargaud@univ-lyon1.fr
• Br. J. Haematol. 2009 Jun 1;145(6):825-35.

AbstractPatients with thrombophilia and/or a history of venous thromboembolism (VTE) exhibit a high risk of thrombosis during pregnancy. The present multicentre study prospectively assessed a prophylaxis strategy, based on a risk score, in pregnancies with increased risk of VTE. Among 286 patients included in the study, 183 had a personal history of VTE (63.98%) and 191 patients (66.8%) had a thrombophilia marker. Eighty nine (46.6%) thrombophilic women had a personal history of VTE. Patients were assigned to one of three prophylaxis strategies according to the risk scoring system. In postpartum, all patients received low molecular weight heparin (LMWH) prophylaxis for at least 6 weeks. In antepartum, LMWH prophylaxis was prescribed to 61.8% of patients with high risk of VTE. Among them, 37.7% were treated in the third trimester only and 24.1% were treated throughout pregnancy. In this cohort, one antepartum-related VTE (0.35%) and two postpartum-related VTE (0.7%) occurred. No case of pulmonary embolism was observed during the study period. The rate of serious bleeding was 0.35%. There was no evidence of heparin-induced thrombocytopenia or osteoporosis. The use of a risk score may provide a rational decision process to implement safe and effective antepartum thromboprophylaxis in pregnant women at high risk of VTE.

31 keywords...

hide…